Vera Therapeutics, Inc.
Financials
Valuation Metrics
Vera Therapeutics, Inc.'s Market Cap is $2.44B. At end of 2025 it was $3.25B. Ranked #1885 of 3,121 in US market (top 60%), #701 of 1,463 on NASDAQ (top 48%), #121 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.44B | US#1,885/3,121 Sec#121/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-402M | US—/3,121 Sec—/266 |
| Total Assets | $533M | US#2,745/3,121 Sec#157/266 |
| Net Assets | $408M | US#2,370/3,121 Sec#134/266 |
| Employees | 361 | US#2,374/3,121 Sec#104/266 |
| Value | ||
| P/B | 5.99x | US#2,352/3,121 Sec#159/266 |
| FCF Yield | -13.89% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -98.56% | US#2,790/3,121 Sec#203/266 |
| ROA | -75.40% | US#3,041/3,121 Sec#243/266 |
| Financial Health | ||
| Debt Ratio | 30.71% | US#348/3,121 Sec#108/266 |
| Total Debt | $75M | US#2,511/3,121 Sec#133/266 |
| FCF | $-339M | US#2,866/3,121 Sec#240/266 |
| Cash | $49M | US#2,585/3,121 Sec#227/266 |
| Current Ratio | 10.92x | US#232/3,121 Sec#71/266 |
| Performance | ||
| 1Y Return | 29.08% | US#719/3,121 Sec#121/266 |
| 1M Return | 5.33% | US#407/3,121 Sec#42/266 |
| From 52W High | -39.34% | US#2,430/3,121 Sec#188/266 |
| 1Y MDD | -48.10% | US#2,372/3,121 Sec#172/266 |
| Trading | ||
| Volume | 4,059,394 shares | US#444/3,121 Sec#39/266 |
| Trading Value | $138M | US#657/3,121 Sec#40/266 |
| Per Share | ||
| EPS | $-5.60 | US—/3,121 Sec—/266 |
| BPS | $5.68 | US#2,226/3,121 Sec#120/266 |
Company Info
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.